Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device

NCT07561567 | Recruiting

• 1 other identifier: TJMUCH358-2023-15
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this clinical trial is to understand the safety and effectiveness of abdominal pressure devices in inhibiting respiratory movement in lung cancer patients. The main question it aims to answer is: Did the abdominal pressure device reduce the respiratory movement of participants with lung cancer tumors? Participants will: Record how much they use abdominal pressure devices to suppress lung cancer tumor respiratory movement

Conditions

Lung Cancer, Non-Small Cell

Keywords

Respiratory Movement Management

Outcome Measures

Primary Outcomes (1)

• Tumor displacement range

  Based on 4DCT for delineating tumor motion range and extracting radiomics features in patients with and without respiratory management

  Within 6 months after enrollment

Study Arms (2)

Breathing management group

CT/4DCT scan under breathing management

Device: Chest and abdominal compression; Device: breathing management

No breathing management group

CT/4DCT scan under free breathing

Interventions

Chest and abdominal compression DEVICE

Abdominal compression suppresses respiratory movement in patients

Breathing management group

breathing management DEVICE

Apply pressure to the patient's abdomen to achieve respiratory movement inhibition

Breathing management group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This trial will enroll 50 patients with NSCLC scheduled to receive SBRT

You may qualify if:

• Clinical diagnosis is solitary peripheral lung cancer, and after comprehensive evaluation by the participating physicians based on the patient's clinical data, it is suitable for receiving SBRT treatment;

You may not qualify if:

• Central or super central lung cancer patients who are intolerant or unwilling to undergo respiratory suppression and chest and abdominal compression fixation

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

Study Sites (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Xuyao Yu Dr

CONTACT

86-022-23341405; yuxuyao@tmu.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2026
• First Posted: May 1, 2026
• Study Start (Estimated): May 10, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: May 1, 2026

Record last verified: 2026-01

Locations

CN (1)